Abstract
Background: This phase II neoadjuvant trial evaluated bevacizumab-docetaxel and carboplatin in triple-negative breast cancer. Patients and methods: Women with hormone receptor- and human epidermal growth factor receptor 2 (HER2)- negative, stage II/III breast cancer received six cycles of 75 mg/m2 docetaxel, carboplatin (AUC = 5) and 15 mg/kg bevacizumab every 21 days. The primary end point was pathological complete response (pCR) in breasts and axillary lymph nodes (ALN). Results: Forty-five patients were recruited from the Korean Cancer Study Group. The median age was 45 (range 30-72) years. ALNs were positive in 80% of patients (n = 36) at diagnosis. Overall, 98% of patients (n = 44) completed therapy and underwent surgery. The pCR rate was 42% (n = 19); clinical response rate 96% (n = 43); complete 13% (n = 6); partial 82% (n = 37); stable disease 2% (n = 1). Breast-conserving surgery was undertaken in 78% of patients (n = 35). Most frequent grade 3/4 adverse events were neutropenia (84%, n = 38) and febrile neutropenia (9%, n = 4). One patient experienced delayed wound healing after surgery. Conclusions: Neoadjuvant bevacizumab, docetaxel and carboplatin resulted in an encouraging pCR rate and negligible wound healing problems after surgery.
| Original language | English |
|---|---|
| Pages (from-to) | 1485-1490 |
| Number of pages | 6 |
| Journal | Annals of Oncology |
| Volume | 24 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - 2013 Jun 1 |
Fingerprint
Keywords
- Bevacizumab
- Carboplatin
- Docetaxel
- Neoadjuvant chemotherapy
- Pathological complete response
- Triple-negative breast cancer
ASJC Scopus subject areas
- Oncology
- Hematology
Cite this
Multicentre phase II trial of bevacizumab combined with docetaxel-carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSGBR-0905). / Kim, H. R.; Jung, K. H.; Im, S. A.; Im, Y. H.; Kang, S. Y.; Park, Kyong Hwa; Lee, S.; Kim, S. B.; Lee, K. H.; Ahn, J. S.; Kim, S. I.; Sohn, J. H.
In: Annals of Oncology, Vol. 24, No. 6, 01.06.2013, p. 1485-1490.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Multicentre phase II trial of bevacizumab combined with docetaxel-carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSGBR-0905)
AU - Kim, H. R.
AU - Jung, K. H.
AU - Im, S. A.
AU - Im, Y. H.
AU - Kang, S. Y.
AU - Park, Kyong Hwa
AU - Lee, S.
AU - Kim, S. B.
AU - Lee, K. H.
AU - Ahn, J. S.
AU - Kim, S. I.
AU - Sohn, J. H.
PY - 2013/6/1
Y1 - 2013/6/1
N2 - Background: This phase II neoadjuvant trial evaluated bevacizumab-docetaxel and carboplatin in triple-negative breast cancer. Patients and methods: Women with hormone receptor- and human epidermal growth factor receptor 2 (HER2)- negative, stage II/III breast cancer received six cycles of 75 mg/m2 docetaxel, carboplatin (AUC = 5) and 15 mg/kg bevacizumab every 21 days. The primary end point was pathological complete response (pCR) in breasts and axillary lymph nodes (ALN). Results: Forty-five patients were recruited from the Korean Cancer Study Group. The median age was 45 (range 30-72) years. ALNs were positive in 80% of patients (n = 36) at diagnosis. Overall, 98% of patients (n = 44) completed therapy and underwent surgery. The pCR rate was 42% (n = 19); clinical response rate 96% (n = 43); complete 13% (n = 6); partial 82% (n = 37); stable disease 2% (n = 1). Breast-conserving surgery was undertaken in 78% of patients (n = 35). Most frequent grade 3/4 adverse events were neutropenia (84%, n = 38) and febrile neutropenia (9%, n = 4). One patient experienced delayed wound healing after surgery. Conclusions: Neoadjuvant bevacizumab, docetaxel and carboplatin resulted in an encouraging pCR rate and negligible wound healing problems after surgery.
AB - Background: This phase II neoadjuvant trial evaluated bevacizumab-docetaxel and carboplatin in triple-negative breast cancer. Patients and methods: Women with hormone receptor- and human epidermal growth factor receptor 2 (HER2)- negative, stage II/III breast cancer received six cycles of 75 mg/m2 docetaxel, carboplatin (AUC = 5) and 15 mg/kg bevacizumab every 21 days. The primary end point was pathological complete response (pCR) in breasts and axillary lymph nodes (ALN). Results: Forty-five patients were recruited from the Korean Cancer Study Group. The median age was 45 (range 30-72) years. ALNs were positive in 80% of patients (n = 36) at diagnosis. Overall, 98% of patients (n = 44) completed therapy and underwent surgery. The pCR rate was 42% (n = 19); clinical response rate 96% (n = 43); complete 13% (n = 6); partial 82% (n = 37); stable disease 2% (n = 1). Breast-conserving surgery was undertaken in 78% of patients (n = 35). Most frequent grade 3/4 adverse events were neutropenia (84%, n = 38) and febrile neutropenia (9%, n = 4). One patient experienced delayed wound healing after surgery. Conclusions: Neoadjuvant bevacizumab, docetaxel and carboplatin resulted in an encouraging pCR rate and negligible wound healing problems after surgery.
KW - Bevacizumab
KW - Carboplatin
KW - Docetaxel
KW - Neoadjuvant chemotherapy
KW - Pathological complete response
KW - Triple-negative breast cancer
UR - http://www.scopus.com/inward/record.url?scp=84878449611&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84878449611&partnerID=8YFLogxK
U2 - 10.1093/annonc/mds658
DO - 10.1093/annonc/mds658
M3 - Article
VL - 24
SP - 1485
EP - 1490
JO - Annals of Oncology
JF - Annals of Oncology
SN - 0923-7534
IS - 6
ER -